Operator: Our next question is from the line of Jack Allen with Baird
Jack Allen: Thanks for taking the questions and congratulations on the team on the progress. My question is also as it relates to the ASH abstracts really impressive results UCART20x22 program. As a first dose level here, as I was wondering, and I see if the team had any comments about the need to escalate dose are you satisfied with the but the early results you are seeing here? Love to hear about that.
Arthur Stril: Yeah Jack, thanks for the question. And yes, I’m as you point out, three out of three responders at the initial dose level. And as also you can see the safety quite good at this dose level as well. And I think given given both of those facts, we will be we will in fact, be escalating those study just, you know, to see where we can get at it, the next higher dose level. So stay tuned for that.
Jack Allen: And then just one brief follow-up on as it relates to longer follow-up on these patients on, can you provide some context around when the data was taken for ASH and what you expect to present at the conference? And then just to clarify on, we should be primarily focused on additional data from the first three patients rather than a second dose cohort as well.
Arthur Stril: Yes. So we’ll we’ll be focusing on the first three patients for the poster presentation.
Jack Allen: Any thoughts on additional kind of follow up there or what kind of thought we could expect from those three patients at the conference?
Arthur Stril: So well, we’ll give some further follow up that we have on them. So please come by and visit us at the poster.
Jack Allen: Great. Thanks so much.
Operator: Our next question is from the line of Salveen Richter with Goldman Sachs
Whitney Watson: Hi, this is Whitney on for Salveen. Thanks, much for taking your question. Could you just remind us of the strategy for UCART20x22 in terms of the targeted patient population given positive data at ASH?
Arthur Stril: Thank you very much for the question that would be for Mark.
Mark Frattini: Hi. Yes, thank you for the question. So you know, we are — is in third-line or greater that we’re using this, and this is prior CD19 failures are also included in this study. So that’s where we’re continuing.
Operator: Our next question is from the line of Silvan Tuerkcan with JMP Securities
Silvan Tuerkcan: Good morning and congrats and thanks for taking my question. My first question is now that you have human data with UCART22 with product 1 and product 2. Do we do we know what why products to so much more potent? You have any metrics reflects a two times or more [Technical Difficulty]. And then a second question is, are there any more near term milestones associated with our schemes, anti CD-70, the or programmes? You could be getting. Thank you so much.
Arthur Stril: Great. Thank you very much for both questions. I’ll hand it over to Andre for the first one.
Andre Choulika: Yes, hi, nice events that and thank you very much for the nice question because I think that the manufacturing that tottaly makes a huge difference. And as Mark described this presentation, there is process one the process that was used at the CMO initially, and the one we’ve implemented after internally this process two. So there’s few that have changed. We know exactly why. One day someone asked me a question in about how we do it, how we can do cells that have so much potency. And let me tell I’m going to share this quick review here online. So I see all the faces around me. Andre don’t do this I’m going to do it. Well, we’ve done close to 10,000 batches internally in the process development. We’ve done and crushed and crushed and crushed cells and tweaked every parameter and there are hundreds of parameter.
This is called experience. We are the ones that have invented the concept of allogenic CAR-T. I can tell you that like the post that didn’t came out like this slide from from the ground, it took a long time before we go to the point where we are. And today, I think that will probably, the best on the planet to do allogenic CAR-T, as Mark said, come at our poster session at at ASH, watch the expansion of the cells, even a super low doses. You will see what it means that such type of experience and experience cannot be invented in a day. It can be transmitted, but we don’t know transmit the 10 years of crushing batch after batch of small, midsize to large size, batch in GMP conditions, et cetera. Up to the time we have tweaked all parameter to perfection.
That’s the answer. And for the Allogene?
Arthur Stril: Thanks, André. And on the Allogene questions. So we definitely have a significant vested interest Allogene success, just remembering upto to $410 million in development and sales milestones for CD- 19 through our agreement with the survey and up to $2.8 billion in development and sales milestones. We haven’t disclosed the granularity of the milestones, but we’ll invest in if you communicate that in when Allogene hit those milestones and we get at the amounts in our back.
Silvan Tuerkcan: Great.Thanks for revealing the secret sauce.
Operator: Our next question is from the line of Yanan Zhu with Wells Fargo
Unidentified Analyst : This is Kwan Kim for Yunnan. So my question is on the new CAR-T 22. So can you give us more detail about the grade by AE now was revealed in the abstract and how that may affect the further study contact? Thank you.
Arthur Stril: Thank you for the question, and this will be for Mark.+
Mark Frattini: So as you know, as we rebuild in the abstract, this grade five events happened after long after several couple of weeks after the day 28 assessment in this patient who had a morphologic leukemia-free state. So as bacterial infection that the investigator related, related to everything, which is why it’s there. So it’s really not affecting anything as we move move ahead.
Unidentified Analyst : Got it. Is there a way to quantify how much of that was contributed by the UCART22 itself or the Thank you.
